Otofacial Neurodevelopmental Syndrome (OFNS) — Comprehensive Research Report

1. Disease Information

Overview. Otofacial neurodevelopmental syndrome (OFNS) is a recently delineated (2024), rare, autosomal recessive neurodevelopmental disorder caused by bi-allelic loss-of-function variants in ZSCAN10. It is characterized by the triad of (1) global developmental delay/intellectual disability, (2) variable facial asymmetry with hypotonic/dysmorphic facies, and (3) outer and inner ear malformations causing sensorineural hearing impairment. The condition was first described in a 2024 Brain paper by Laugwitz et al., "ZSCAN10 deficiency causes a neurodevelopmental disorder with characteristic oto-facial malformations" (PMID: 38386308), based on 7 affected individuals from 5 unrelated families.

Key identifiers: | Resource | ID | |---|---| | OMIM (phenotype) | #620910 — OTOFACIAL NEURODEVELOPMENTAL SYNDROME; OFNS | | OMIM (gene) | *618365 — ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 10; ZSCAN10 | | MONDO | MONDO:0975705 | | MedGen | UID 1857968 / UMLS C5935642 | | HGNC gene symbol | ZSCAN10 (formerly ZNF206) | | NCBI Gene ID (human) | 84891 | | Ensembl gene | ENSG00000130182 (chr16:3,088,890–3,099,295, GRCh38) | | Orphanet / ICD-10/11 | Not yet assigned as of this writing — the disorder is too recently described (2024) to have an Orphanet or ICD entry; not found in Orphanet or WHO ICD searches during this research |

Synonyms: OFNS; ZSCAN10 deficiency; ZSCAN10-related neurodevelopmental disorder.

Evidence basis: All currently available clinical information derives from a single aggregated case-series publication (7 patients, 5 families) plus corroborating mouse and cell-line (mESC) functional data — this is an aggregated disease-level literature resource, not an EHR-derived cohort. There is no disease registry, natural-history study, or additional independent case series published yet (as of the July 2026 literature search performed for this report).

2. Etiology

Disease causal factor: OFNS is a monogenic disease caused by bi-allelic (homozygous or compound heterozygous) protein-truncating (loss-of-function) variants in ZSCAN10 (chromosome 16p13.3). No environmental, infectious, or multifactorial causal contribution has been reported — it is a purely Mendelian, single-gene neurodevelopmental disorder.

Genetic risk factors: - All 5 families' variants are protein-truncating variants (PTVs) clustered in the terminal coding exon (exon 6), which encodes 66% of the protein (518/780 amino acids) including 13–14 of the 14 C2H2 zinc-finger DNA-binding motifs. - Variants identified (PMID:38386308): - c.1456C>T, p.Gln486 — homozygous in families F2, F4, F5 (5 individuals); population allele frequency ~7×10⁻⁴ in gnomAD South Asian subpopulation (17 heterozygotes; no homozygous PTVs observed in gnomAD v2.1.1), consistent with a possible South Asian founder allele. - c.1112del, p.Pro371Argfs49 — homozygous in family F1. - c.1250C>A, p.Ser417 and c.2050del, p.His684Thrfs153 — compound heterozygous in family F3. - Founder effect: Families F2 and F5 shared runs of homozygosity (2.5–8.1 Mb) around the c.1456C>T allele, suggesting a shared ancestral haplotype in individuals of South/West Asian origin (Turkish, Iranian, Indian, Pakistani). - Consanguinity: Consistent with autosomal recessive inheritance and the predominantly consanguineous/endogamous populations sampled (Turkey, Iran, India, Pakistan). - Because all reported variants escape nonsense-mediated decay (they lie downstream of the last exon-junction complex), the mechanism is truncated-protein production with loss/mislocalization of function, not simple haploinsufficiency via mRNA degradation.

Protective factors: None reported; no protective variants or modifier alleles have been described for ZSCAN10-related disease.

Gene-environment interactions: None reported; no environmental modifiers of expressivity have been studied given the extreme rarity and recency of the disorder's description.

3. Phenotypes

All phenotype data below is drawn from the 7-patient cohort in Laugwitz et al. 2024 (PMID:38386308).

Onset: Congenital/present from birth (ear malformations, facial asymmetry evident perinatally); developmental delay recognized in infancy/early childhood. Severity/progression: Non-progressive, static congenital malformation plus a stable-to-slowly-clarifying developmental delay course (typical of a structural/transcription-factor neurodevelopmental disorder rather than a degenerative one); severity is variable across the cognitive spectrum (mild to profound). Quality of life impact: Not formally measured (no EQ-5D/SF-36/PROMIS data reported); qualitatively, hearing loss and developmental delay are expected to impact communication, education, and adaptive functioning; behavioral features (aggression, autistic traits) may affect social functioning. No disease-specific QOL instrument exists yet given the 2024 initial description.

4. Genetic/Molecular Information

Causal gene: ZSCAN10 (Zinc Finger and SCAN Domain Containing 10; alias ZNF206), HGNC-approved symbol ZSCAN10, NCBI Gene ID 84891, located at 16p13.3 (OMIM *618365).

Variant classification/type: All four distinct variants identified to date are protein-truncating variants (PTVs) — one frameshift deletion pair and two nonsense (stop-gain) variants — clustered in the final coding exon (exon 6). Per ACMG/AMP framework these would be classified pathogenic/likely pathogenic on the basis of: PVS1-adjacent truncating location within a critical functional domain (loss of 13–14 zinc fingers), absence of homozygotes in population databases, full co-segregation with phenotype in available family members, and functional validation (mislocalization + loss of DNA binding).

Population allele frequency: The recurrent c.1456C>T (p.Gln486) allele occurs at ~7×10⁻⁴ in the gnomAD South Asian subpopulation (17 heterozygous carriers, v2.1.1), with zero homozygous PTV carriers* reported in gnomAD generally — consistent with a rare recessive disease allele under purifying selection against the homozygous state, and with a South/West Asian founder effect.

Somatic vs. germline: All variants reported are germline, inherited in autosomal recessive fashion; no somatic mosaicism reported.

Functional consequences (loss of function): - Wild-type ZSCAN10 protein localizes to the nucleus; the truncated mutant protein (e.g., ZSCAN10^485 from c.1456C>T) is instead mainly cytoplasmic — i.e., the truncation disrupts nuclear import/localization. - ChIP-qPCR shows the mutant protein loses DNA-binding capacity at the POU5F1 (OCT4) promoter, a direct ZSCAN10 target, versus strong wild-type binding. - RNA-seq in Zscan10⁻/⁻ mouse embryonic stem cells (mESCs) shows 1,310 differentially expressed genes (710 down, 600 up; FDR<0.05), including dysregulation of pluripotency/developmental genes Pou5f1, Sall4, Mtf2, Hoxb13, Meis2. KEGG pathway analysis flagged "ATP-dependent chromatin remodeling" as the top affected pathway among downregulated genes. - Direct quote (PMID:38386308): "Loss of ZSCAN10 function is the likely consequence and pathomechanism of the identified disease alleles" and "Loss of ZSCAN10 dysregulates several genes associated with pluripotency and differentiation of ESCs."

Modifier genes: None identified/reported.

Epigenetic information: No disease-specific DNA methylation, histone modification, or chromatin-mark studies have been reported in patients; the mechanistic link is via ZSCAN10's role as a transcriptional/chromatin-remodeling regulator rather than via an epigenetic mark on the ZSCAN10 locus itself.

Chromosomal abnormalities: None reported — OFNS is caused by small intragenic PTVs, not by copy-number/structural chromosomal rearrangements. (Note: a phenotypically distinct entity, "Chromosome 16p13.3 duplication syndrome," exists in the same cytogenetic region but is a separate, contiguous-gene-duplication condition, not OFNS — flagged here to avoid Named Entity Confusion.)

5. Environmental Information

No environmental, lifestyle, or infectious contributing factors have been identified or are biologically plausible for this monogenic transcription-factor disorder. Not applicable.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream): 1. Molecular trigger: Bi-allelic PTVs in ZSCAN10 exon 6 → truncated protein lacking most C2H2 zinc-finger DNA-binding motifs. 2. Subcellular consequence: Loss of nuclear localization (mutant protein mislocalizes to cytoplasm) → loss of transcription-factor access to target gene promoters. 3. Molecular/transcriptional consequence: Loss of ZSCAN10 binding at target promoters, including POU5F1 (OCT4) → dysregulation of pluripotency/developmental transcriptional network (Pou5f1, Sall4, Mtf2, Hoxb13, Meis2) and of ATP-dependent chromatin-remodeling pathway genes. 4. Cellular/developmental consequence: Disrupted transcriptional regulation during embryonic stem cell maintenance/early differentiation programs affecting cranial neural crest- and otic placode-derived structures. 5. Tissue/organ consequence: Aberrant morphogenesis of first/second pharyngeal-arch-derived facial structures (facial asymmetry) and otic-vesicle-derived structures (outer ear, semicircular canals, cochlea) → structural malformation and secondary sensorineural hearing loss; disrupted CNS developmental gene networks → global developmental delay/intellectual disability. 6. Organism-level manifestation: The OFNS clinical triad (developmental delay + facial asymmetry + oto-facial malformation/hearing loss), plus variably penetrant additional features (micropenis, cardiac defect, cleft palate, behavioral abnormalities).

Molecular pathway: ZSCAN10 acts as a C2H2 zinc-finger/SCAN-domain transcription factor operating within (and adjacent to) the core pluripotency transcriptional network alongside OCT4 (POU5F1), SOX2, and NANOG in embryonic stem cells, with genome-wide ChIP evidence of >3,000 binding sites, 183 of which overlap the OCT4/SOX2/NANOG trio — consistent with both direct and indirect roles in orchestrating developmental gene-regulatory programs. Suggested GO terms: GO:0003700 (DNA-binding transcription factor activity), GO:0000981 (RNA polymerase II-specific DNA-binding transcription factor activity), GO:0019827/GO:1902459 (stem cell population maintenance / positive regulation thereof), GO:0006338 (chromatin remodeling; specifically ATP-dependent chromatin remodeling per the KEGG-flagged pathway).

Cellular processes: Disrupted stem-cell transcriptional maintenance and differentiation-associated chromatin remodeling during embryogenesis (not apoptosis, autophagy, or classic inflammatory mechanisms). Suggested CL term: CL:0002322 (embryonic stem cell) as the primary cellular substrate studied.

Protein dysfunction: Loss-of-function via truncation — loss of most zinc-finger DNA-binding domains plus aberrant subcellular localization (nuclear-to-cytoplasmic mislocalization of the truncated protein), rather than a gain-of-function or dominant-negative mechanism. Note a contextual duality: separate oncology literature (PMID:31933877) reports ZSCAN10 overexpression promoting glioma proliferation via OCT4 upregulation and Wnt/β-catenin activation — the inverse (gain-of-function/oncogenic) context, underscoring that ZSCAN10's normal role is dosage-sensitive and context-dependent. This is mechanistically distinct from OFNS and should not be conflated with the germline loss-of-function disease mechanism.

Immune system involvement: None reported/implicated.

Tissue damage mechanisms: Not applicable — this is a developmental morphogenesis defect (malformation) rather than a degenerative or injury-based tissue-damage mechanism.

Molecular profiling performed to date: - Transcriptomics: RNA-seq of Zscan10⁻/⁻ vs wild-type mESCs (1,310 DEGs) — PMID:38386308. - Genomic structural features: 3D geometric morphometric analysis of mouse embryonic craniofacial and inner-ear structures at E14.5 (26 surface landmarks + 22 inner-ear landmarks; Procrustes superimposition and fluctuating-asymmetry analysis). - ChIP-qPCR: confirming direct ZSCAN10–Pou5f1 promoter binding, lost in the truncated mutant. - No proteomics, metabolomics, lipidomics, single-cell, or spatial transcriptomic data have yet been published for this disorder.

7. Anatomical Structures Affected

Organ level: - Primary: Face (asymmetry, dysmorphic features), outer ear (microtia, low-set/posteriorly rotated position, absent superior crus), inner ear (semicircular canal dysplasia, cochlear shortening in the mouse model), brain/CNS (developmental delay/intellectual disability — no structural cerebral anomalies noted on MRI beyond the otic findings). - Secondary: Cardiovascular (mild left ventricular enlargement, 1/7), palate (cleft palate, 1/7), genitourinary (micropenis, cryptorchidism), eyes (visual impairment in 3/7, mechanism unspecified). - Body systems involved: nervous system, craniofacial/musculoskeletal (ear/face), auditory/vestibular system, cardiovascular system, genitourinary system.

Suggested UBERON terms: UBERON:0000980 (face), UBERON:0001756 (external ear / outer ear), UBERON:0001846 (inner ear... note: verify exact ID via OAK — likely UBERON:0001846 for inner ear or UBERON:0002105 depending on version), UBERON:0001850 (semicircular canal), UBERON:0001844 (cochlea), UBERON:0001987 (palate).

Tissue and cell level: Craniofacial/pharyngeal-arch-derived neural-crest mesenchyme and otic-vesicle/otic-placode-derived epithelium are the developmental substrates implicated (inferred from the malformation pattern and mouse embryo findings), alongside the broadly studied embryonic stem cell (CL:0002322) as the in vitro model system for molecular mechanism.

Subcellular level: Nucleus (site of normal ZSCAN10 transcription-factor activity; GO Cellular Component GO:0005634) versus cytoplasm (site of aberrant mutant-protein mislocalization; GO:0005737).

Localization/laterality: Facial asymmetry and ear malformations are frequently bilateral but asymmetric in severity, sometimes strictly unilateral (2/7 unilateral outer-ear malformation; hearing loss ranging from unilateral to bilateral) — a distinctive "fluctuating asymmetry" pattern rather than fixed bilateral symmetry, also reproduced and quantified in the Zscan10⁻/⁻ mouse model.

8. Temporal Development

Onset: Congenital — facial asymmetry and ear malformations are present from birth; developmental delay is recognized in infancy/early childhood. No adult-onset or late-onset presentation reported. Onset pattern: Insidious/congenital structural and developmental (not acute). Progression: The malformative features (ear/face) are static/non-progressive congenital anomalies; the neurodevelopmental phenotype (developmental delay, cognitive impairment) is a stable, non-degenerative deficit typical of a transcriptional-regulator neurodevelopmental disorder — no reported evidence of regression or progressive decline. Disease course pattern: Stable, chronic, lifelong (congenital malformation + static neurodevelopmental impairment); not episodic or relapsing-remitting. Disease stages: Not formally staged — disease is not classified by stage/grade systems (unlike cancers). Remission patterns: Not applicable (congenital structural/developmental disorder, not a remitting condition). Critical periods: Embryonic craniofacial and otic morphogenesis (first-second pharyngeal arch and otic vesicle development, roughly corresponding to human 4th–8th gestational weeks by analogy to the mouse E14.5 model timepoint) represents the developmental window of vulnerability, based on the mouse embryo phenotyping timepoint.

9. Inheritance and Population

Epidemiology: Extremely rare — only 7 affected individuals from 5 families reported worldwide as of the founding 2024 publication; no formal prevalence or incidence estimate exists (likely well below 1/1,000,000; the disorder would fall in an ultra-rare/"cases in literature" prevalence class per Orphanet-style banding, with prevalence_class: NOT_YET_DOCUMENTED or CASES_IN_LITERATURE being the most defensible dismech curation choice).

Inheritance pattern: Autosomal recessive (AR) — confirmed by bi-allelic (homozygous or compound heterozygous) variant findings and full co-segregation with phenotype in family members tested.

Penetrance: Appears complete for the core phenotype (developmental delay + ear malformation) among the 7 reported bi-allelic carriers, though expressivity is markedly variable (see below); formal penetrance estimates are not available given the small cohort.

Expressivity: Highly variable — cognitive impairment ranges mild to profound; facial asymmetry present in 5/7; hearing loss severity ranges unilateral-mild to bilateral-profound; additional features (cardiac defect, cleft palate, micropenis, behavioral abnormalities) are present in only a subset, indicating variable expressivity even among carriers of the identical recurrent allele (c.1456C>T).

Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).

Germline mosaicism: Not reported.

Founder effects: Strong evidence for a South/West Asian founder allele at c.1456C>T (p.Gln486*), shared among Turkish, Iranian, Indian, and Pakistani families, supported by shared runs of homozygosity (2.5–8.1 Mb) in families F2 and F5 and elevated allele frequency specifically in the gnomAD South Asian subpopulation.

Consanguinity role: Likely significant, consistent with the populations sampled and the autosomal recessive homozygous presentations in most families.

Carrier frequency: Estimated from gnomAD: ~7×10⁻⁴ heterozygote frequency for c.1456C>T specifically in the South Asian gnomAD subpopulation (i.e., roughly 1 in ~1,400 in that specific reference subpopulation); overall population carrier frequency across all ZSCAN10 PTV alleles is not separately reported.

Population demographics: All reported families are of Turkish (1), Iranian (4), Indian (1), and Pakistani (1) origin — a South/West/Central Asian geographic clustering, likely reflecting both the founder allele and ascertainment bias (genetic referral centers with expertise in consanguineous-population Mendelian disease gene discovery) rather than necessarily reflecting the disorder's true global geographic distribution. Sex ratio: 3 females : 4 males reported — roughly equal, consistent with autosomal (non-X-linked) inheritance. Age distribution: Patients examined ranged from 1 year 8 months to 15 years at time of report — a pediatric/adolescent cohort; no adult patients yet described (disease is presumably lifelong but long-term adult natural history is unknown).

10. Diagnostics

Laboratory tests / biomarkers: No specific diagnostic biochemical or serum biomarker exists; diagnosis is genetic/imaging-based, not biochemical.

Imaging studies: - MRI of the temporal bone/inner ear: demonstrated bilateral semicircular canal dysplasia in both patients with available imaging (2/2), plus subtle osseous asymmetry of the skull and midface; no other cerebral structural anomalies identified. - 3D facial/craniofacial imaging: used in the mouse model (geometric morphometrics) and, in patients, computational facial-analysis tools (GestaltMatcher) were applied to frontal facial photographs to validate the facial-asymmetry phenotype, achieving 82% (41/50) correct classification for asymmetry detection, with all 6 affected individuals' frontal images correctly classified.

Functional tests / electrophysiology: - Audiology (audiometry): sensorineural hearing loss documented in 4/5 tested individuals, ranging from unilateral deafness to profound bilateral loss. No vestibular symptoms (vertigo/imbalance) reported despite structural inner-ear pathology.

Biopsy/pathology: Not applicable/not performed — this is a structural developmental disorder, not evaluated by tissue biopsy.

Genetic testing: - Recommended approach: Given the phenotype's rarity and gene-discovery status (2024), diagnosis currently relies on exome or genome sequencing (the modality by which all 7 reported cases were identified) rather than a targeted panel, as ZSCAN10 is unlikely to yet be included on most commercial hearing-loss or intellectual-disability gene panels. - WES/WGS utility: High — this is precisely how the causal gene was discovered (trio/family exome sequencing with homozygosity mapping in consanguineous families). - Single-gene testing: Feasible for confirmed familial variants once identified in a proband (e.g., targeted Sanger confirmation of the recurrent c.1456C>T allele in South Asian families). - Chromosomal microarray/karyotype/FISH: Not the diagnostic modality of choice (disease is due to small intragenic PTVs, not copy-number/structural chromosomal changes), though may be used to exclude a differential such as 16p13.3 duplication/deletion syndrome. - Mitochondrial DNA / repeat-expansion testing: Not applicable.

Omics-based diagnostics: Not yet in routine/research diagnostic use for this disorder; RNA-seq and ChIP-qPCR were used as research validation tools (mESC model), not as clinical diagnostic assays.

Clinical criteria: No formal consensus diagnostic criteria (DSM/ICD/society guidelines) yet exist, given the 2024 initial description; diagnosis currently rests on the combination of (a) bi-allelic ZSCAN10 PTV and (b) the characteristic phenotypic triad (developmental delay + facial asymmetry + oto-facial malformation/hearing loss).

Differential diagnosis: Should include other syndromic causes of combined craniofacial-asymmetry + ear-malformation + developmental delay, e.g., oculo-auriculo-vertebral spectrum (Goldenhar/hemifacial microsomia), CHARGE syndrome, branchio-oto-renal spectrum disorders, and other zinc-finger transcription-factor neurodevelopmental disorders — though a detailed differential-diagnosis discussion was not part of the identified literature and would benefit from independent verification.

Screening: No newborn or population screening program exists (disease too rare/recently described); no cascade or carrier screening program established, though targeted carrier testing for the recurrent c.1456C>T allele could be considered in high-risk South/West Asian consanguineous families given the founder-effect data.

11. Outcome/Prognosis

Survival/mortality: No mortality data reported among the 7 described patients; no evidence the condition is life-limiting based on available data, though the cohort is small and long-term follow-up is not yet published.

Morbidity/function: Long-term functional outcomes are not systematically reported; morbidity is driven by the combination of intellectual disability (mild-to-profound), hearing impairment (unilateral to profound bilateral sensorineural loss), and — in a subset — cardiac, palatal, or genitourinary anomalies requiring their own management.

Quality of life measures: None formally reported/available.

Complications: Feeding/speech difficulties secondary to cleft palate (1/7); potential cardiac monitoring needs for the individual with LV enlargement; genitourinary complications (undescended testis) requiring surgical correction; behavioral complications (aggression, autistic features) impacting social/adaptive function.

Recovery potential: Not a degenerative disease — the structural anomalies are fixed/congenital and the neurodevelopmental impairment is expected to be a static (not progressive) encephalopathy-type course, so "recovery" in the sense of reversal is not expected, but developmental gains with early intervention are plausible by analogy to other neurodevelopmental disorders (not disease-specifically demonstrated yet).

Prognostic factors: Not yet established given the small cohort; qualitatively, the marked variable expressivity (mild-to-profound cognitive range) suggests that individual outcome cannot currently be predicted from genotype alone (multiple individuals shared the identical c.1456C>T allele yet had differing symptom severity).

Prognostic biomarkers: None identified.

12. Treatment

No disease-specific/targeted therapy exists for OFNS (a very recently described monogenic disorder); management is supportive and multidisciplinary, addressing each component of the phenotype by extrapolation from standard care for its constituent features. No treatment outcome data (response rates, disease-specific trial results) exist for OFNS itself.

Pharmacotherapy: No specific pharmacological treatment targets ZSCAN10 or its pathway; symptomatic pharmacotherapy (e.g., for behavioral features such as aggression) would follow standard neurodevelopmental-disorder practice, not disease-specific evidence. Suggested NCIT term: NCIT:C15986 (Pharmacotherapy), used only for symptomatic/behavioral management, not disease-modifying treatment.

Advanced therapeutics: No gene therapy, cell therapy, RNA-based therapy, targeted therapy, or immunotherapy has been developed or trialed for OFNS. Given the loss-of-function truncating mechanism, gene-replacement/augmentation strategies are theoretically conceivable but entirely unstudied/speculative — should not be curated as an actual treatment.

Surgical/interventional: - Cleft palate repair — standard surgical correction for the 1/7 patient with cleft palate. NCIT: NCIT:C15329 (Surgical Procedure). - Orchidopexy for cryptorchidism/maldescended testis. NCIT: NCIT:C15329 (Surgical Procedure) or more specific urologic term if available. - Cochlear implantation may be indicated for patients with profound bilateral sensorineural hearing loss (standard-of-care extrapolation, not disease-specifically reported). - Reconstructive otoplasty may be considered for microtia/outer-ear malformation as in other syndromic microtia conditions (extrapolated, not disease-specifically reported).

Supportive/rehabilitative care: - Hearing aids for less-than-profound sensorineural hearing loss (no dedicated NCIT term exists for "hearing aid usage" per the dismech NCIT remapping notes). - Speech-language therapy — NCIT:C159273 (Speech Therapy) — for delayed/absent speech. - Physical/occupational therapy — NCIT:C15302 (Physical Therapy) / NCIT:C121351 (Occupational Therapy) — for motor delay. - Developmental/early intervention programs and special-education support for global developmental delay/intellectual disability. - Behavioral therapy for autistic features, aggression, and stereotypy. - Genetic counseling — NCIT:C15240 (Genetic Counseling) — for recurrence-risk counseling in autosomal recessive inheritance, particularly relevant given the consanguinity/founder-allele context. - Cardiology follow-up for the subset with cardiac defects.

Experimental treatments: None identified in ClinicalTrials.gov or the literature search for ZSCAN10/OFNS specifically as of this report.

Treatment strategy: No published treatment algorithm exists; management is individualized and multidisciplinary (genetics, otolaryngology/audiology, cardiology, urology, developmental pediatrics, speech/OT/PT), following general principles for syndromic neurodevelopmental disorders rather than an OFNS-specific protocol.

13. Prevention

Primary prevention: Not applicable in the classic sense (this is a Mendelian genetic disease, not preventable by risk-factor modification); the only "primary prevention" lever is reproductive/genetic counseling in at-risk (consanguineous, or carriers of the South Asian founder allele) families, including discussion of preimplantation genetic diagnosis (PGD) or prenatal testing once a familial variant is known.

Secondary prevention: Early diagnosis via genetic testing in families with a known proband, followed by early audiological/developmental screening and intervention to mitigate downstream functional impact of hearing loss and developmental delay.

Tertiary prevention: Multidisciplinary management (above) to prevent/minimize complications (e.g., surgical correction of cleft palate to prevent feeding/speech complications; hearing amplification/cochlear implantation to mitigate the impact of hearing loss on language development).

Immunization: Not applicable — no infectious component.

Screening/genetic counseling: Carrier screening for the recurrent c.1456C>T allele could be considered in high-risk South/West Asian consanguineous populations given the demonstrated founder effect, though no formal population carrier-screening program has been established. Prenatal testing/PGD is feasible once a familial pathogenic variant is identified.

Public health/environmental interventions: Not applicable (no environmental risk factor identified).

Prophylaxis: Not applicable.

14. Other Species / Natural Disease

No naturally occurring ZSCAN10-deficient disease has been reported in companion animals or wildlife (no OMIA entry identified in this search). ZSCAN10 orthologs exist across mammals (e.g., mouse Zscan10, NCBI Gene; rat Zscan10, RGD:1310745; dog ZSCAN10, NCBI Gene 490045), but disease association has only been established via engineered knockout models (see Model Organisms below), not spontaneous natural disease in non-human species.

15. Model Organisms

Primary model: Mouse (Mus musculus), Zscan10 knockout — the core functional-validation model in the founding paper (PMID:38386308). - Model type: Genetically engineered knockout-first allele, Zscan10^tm2a(EUCOMM)Wtsi, generated via a LacZ-cassette insertion upstream of exon 6 (International Mouse Phenotyping Consortium / EUCOMM resource lineage). This model reportedly showed higher embryonic lethality than previously published Zscan10 knockout models. - Phenotype recapitulation (E14.5 embryos): - Significant fluctuating facial asymmetry compared to wild-type littermates (quantified via 3D geometric morphometrics, 26 surface landmarks, Procrustes superimposition). - Smaller eye size and ear opening on 3D imaging. - Misalignment of the semicircular canals and shortening of the cochlea (22-landmark inner-ear 3D morphometric analysis) — directly recapitulating the human inner-ear dysplasia phenotype. - Skull-shape differences on principal component analysis of symmetric shape variation. - Model limitations: The knockout model is embryonic-lethal at higher rates than prior alleles, limiting study to embryonic timepoints (E14.5) rather than postnatal/adult phenotyping (e.g., postnatal hearing function, adult behavior, or long-term developmental outcomes cannot be directly assessed in a highly embryonic-lethal line). No mouse behavioral/cognitive phenotyping (correlating to the human developmental delay/intellectual disability phenotype) was reported in the available search results. - Research applications: Craniofacial and inner-ear developmental morphogenesis; validating the causal role of Zscan10 loss in the oto-facial malformation phenotype independent of possible confounding in human genetic background. - Resource: IMPC/EUCOMM allele resources (MGI database).

Secondary model: Mouse embryonic stem cells (mESCs), Zscan10⁻/⁻ — an in vitro cellular model used for transcriptomic and mechanistic (ChIP-qPCR, subcellular localization) studies described in Section 6/4 above (PMID:38386308). This model recapitulates the molecular-level pathomechanism (transcriptional dysregulation of pluripotency/developmental genes, loss of POU5F1 promoter binding) but does not model the whole-organism phenotype.

Related, disease-adjacent (not disease-causing) model literature on Zscan10 biology (informative for mechanism, not for OFNS phenotype recapitulation per se): - Cai et al., "Pleiotropic Functions for Transcription Factor Zscan10" (PLoS ONE; PMID available via PMC4128777) — establishes Zscan10's genome-wide binding-site profile and role alongside Oct4/Sox2/Nanog in ESC gene regulation. - Nagelreiter et al., "Zscan10 is dispensable for maintenance of pluripotency in mouse embryonic stem cells" (PMID: 26592664) — an important nuance/caveat: this earlier study found Zscan10 was not required for baseline ESC self-renewal/pluripotency maintenance under standard culture conditions, which contextualizes the newer OFNS paper's findings as revealing a developmental (in vivo, organismal) rather than a strict cell-autonomous pluripotency-maintenance requirement — a good candidate for a HUMAN_MODEL_MISMATCH/nuance discussion node if curated into dismech, since apparent mESC dispensability contrasts with clear organismal necessity for normal craniofacial/otic development. - Ma et al., "ZSCAN10 promotes cell proliferation, upregulates OCT4 expression, and activates Wnt/β-catenin signaling in glioma" (PMID: 31933877) — describes an oncogenic, gain-of-function-type role for ZSCAN10 in glioma, mechanistically distinct from (and not to be conflated with) the germline loss-of-function OFNS mechanism; useful context for the gene's normal dosage-sensitive biology but not itself an OFNS model.

Other species (non-model, orthology only): No functional disease modeling reported in zebrafish, Drosophila, C. elegans, or yeast for ZSCAN10/OFNS in the available search results.

Summary Evidence Table (Primary Citations)

Curatorial caveats for dismech entry construction: 1. All PMIDs above must be independently fetched (just fetch-reference PMID:XXXX) and snippets validated against cached abstracts before use — this report's quotes were extracted via web fetch of the PMC full text, not yet run through the dismech reference-validation pipeline. 2. Orphanet and ICD identifiers could not be confirmed as existing yet for this very recently named condition (2024) — do not fabricate an Orphanet/ICD code; leave absent or explicitly note "not yet assigned" pending independent verification at curation time. 3. HPO term IDs suggested above (especially for semicircular canal dysplasia, downslanted palpebral fissures, epicanthus) should be verified with OAK (uv run runoak -i sqlite:obo:hp info <ID> -O obo) before committing to the KB, per standard dismech term-validation practice. 4. Given the extreme rarity/recency (single founding publication), this entry is a strong candidate for conservative curation with heavy reliance on notes: for claims lacking a directly quotable snippet, and appropriate use of MECHANISTIC_HYPOTHESIS/HUMAN_MODEL_MISMATCH framing for extrapolated (not disease-specifically demonstrated) treatment and prognosis content.

Sources: - Otofacial neurodevelopmental syndrome (Concept Id: C5935642) - MedGen - NCBI - Otofacial Neurodevelopmental Syndrome - MalaCards - Entry - #620910 - OTOFACIAL NEURODEVELOPMENTAL SYNDROME; OFNS - OMIM - Clinical Synopsis - #620910 - OMIM - otofacial neurodevelopmental syndrome - Monarch Initiative - ZSCAN10 deficiency causes a neurodevelopmental disorder with characteristic oto-facial malformations - Brain (Oxford Academic) - ZSCAN10 deficiency causes a neurodevelopmental disorder with characteristic oto-facial malformations - PMC - Entry - *618365 - ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 10; ZSCAN10 - OMIM - ZSCAN10 Gene - GeneCards - Pleiotropic Functions for Transcription Factor Zscan10 - PLOS ONE / PMC - Zscan10 is dispensable for maintenance of pluripotency in mouse embryonic stem cells - PubMed - ZSCAN10 promotes cell proliferation, upregulates OCT4 expression, and activates Wnt/β-catenin signaling in glioma - PMC - ZSCAN10 zinc finger and SCAN domain containing 10 [Homo sapiens] - Gene - NCBI - Gene: ZSCAN10 (ENSG00000130182) - Ensembl